Go to main page


Paving the Road to the Clinic: Translational Oncology & Immuno-oncology Tumor Models

June 14, 2018

Register to view on-demand recording

    You may unsubscribe from these communications at any time. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list. For more information on our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Understanding Patient Response to Treatment Before Entering the Clinic

Recent advancements in immunotherapy are shifting the way that cancer is treated. The development of immuno-oncology therapies is creating the need for programs tailored to subsets of patients who are most likely to respond positively to treatment. Predictive preclinical models and translational strategies are needed to understand which patient populations will benefit from treatment and identify biomarkers of response.

This presentation covers:

  • Importance of the tumor microenvironment
  • In vivo models and translational results
  • PDX Case Study: Building Confidence in NSCLC Clinical Population
  • Preclinical profiling of patient populations


Tommy Broudy, PhD

Executive VP, Translational Sciences & Strategy, BioDuro